1. Atherectomy plus antirestenotic therapy for SFA lesions: evolving evidence for better patency rates in complex lesions
- Author
-
Michael Lichtenberg and Grigorios Korosoglou
- Subjects
Male ,medicine.medical_specialty ,Atherectomy ,Drug coated balloon ,medicine.medical_treatment ,Constriction, Pathologic ,030204 cardiovascular system & hematology ,Revascularization ,Peripheral Arterial Disease ,03 medical and health sciences ,0302 clinical medicine ,Coated Materials, Biocompatible ,Recurrence ,Risk Factors ,Angioplasty ,medicine ,Humans ,Vascular Patency ,Endovascular treatment ,Vascular Calcification ,Aged ,Aged, 80 and over ,business.industry ,Debulking Procedure ,Cardiovascular Agents ,General Medicine ,Middle Aged ,Femoral Artery ,Treatment Outcome ,030228 respiratory system ,Female ,Surgery ,Radiology ,Cardiology and Cardiovascular Medicine ,business ,Long lesions ,Angioplasty, Balloon ,Vascular Access Devices - Abstract
Within the last years, many new endovascular treatment modalities have been invented for treatment of peripheral arterial disease. To leave nothing behind and to keep options for future treatment are key issues of these new revascularization procedures. Drug coated balloon technology (DCB) is one key element in this strategy but there are still limitations for this revascularization technology. Especially calcium rich lesions and long lesions are still challenging in terms of treatment success and long-term patency. Treatment of both calcified and long lesions continues to be a clinical challenge for every interventionalists. Therefore, a treatment combination of debulking procedure using atherectomy plus antirestenotic therapy using DCB seems to be promising to treat complex lesions.
- Published
- 2019
- Full Text
- View/download PDF